E. Hitt Nichols

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Fatima Karzai, David James VanderWeele, Ravi A. Madan et al. · Journal for ImmunoTherapy of Cancer · 2018 · 295 citations · Full text

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget et al. · Clinical Cancer Research · 2020 · 209 citations · Full text

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Alexandra S. Zimmer, E. Hitt Nichols, Ashley Cimino‐Mathews et al. · Journal for ImmunoTherapy of Cancer · 2019 · 109 citations · Full text

A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

J.-M. Lee, Christina M. Annunziata, Nicole Houston et al. · Annals of Oncology · 2018 · 33 citations · Full text